Vincristine

Manufactured by MedChemExpress

Sourced in United States

Vincristine is a laboratory product that functions as a chemical compound. It is used for research purposes in life science applications.

Automatically generated - may contain errors

Lab products found in correlation

Spelling variants of this product

Vincristine sulfate (3 citations)

4 protocols using vincristine

Evaluation of Anti-Cancer Compound Effects

Check if the same lab product or an alternative is used in the 5 most similar protocols

DHW-221 was synthesized and purified as described previously (23 (link)). GDC-0980 and MG132 were obtained from Bide Pharmtech Ltd. (Shanghai, China). Taxol, docetaxel, vincristine, cisplatin, verapamil, and cycloheximide (CHX) were purchased from MedChem Express (NJ, USA). Rhodamine (Rho-123) and crystal violet were obtained from Shanghai Maclin Biochemical Co., Ltd. (Shanghai, China). Hoechst 33342 and 4,6-diamino-2-phenyl indole (DAPI) were obtained from Beyotime Biotechnology (Nanjing, China). The Annexin-V fluorescein isothiocyanate (FITC)/PI-double staining apoptosis detection kit and propidium iodide (PI) were obtained from Becton, Dickinson and Company (NJ, USA). P-gp antibody (CST, #13978; Rabbit, AF5185), PI3Kp110α antibody (rabbit, AF5112), p-FOXO3a (Ser253) antibody (rabbit, AF3020), and Bim antibody (Rabbit, AF0121) were purchased from Affinity Biosciences Pty Ltd. (Melbourne). Lactic dehydrogenase (LDH) detection kit (WL03271) and other primary antibodies were purchased from Wanlei Biotechnology Co., Ltd. (Shenyang, China)

Liu M., Xu C., Qin X., Liu W., Li D., Jia H., Gao X., Wu Y., Wu Q., Xu X., Xing B., Jiang X., Lu H., Zhang Y., Ding H, & Zhao Q. (2022). DHW-221, a Dual PI3K/mTOR Inhibitor, Overcomes Multidrug Resistance by Targeting P-Glycoprotein (P-gp/ABCB1) and Akt-Mediated FOXO3a Nuclear Translocation in Non-small Cell Lung Cancer. Frontiers in Oncology, 12, 873649.

+ Open protocol

+ Expand

Chemotherapeutic Drugs Evaluation Protocol

Cited 2 times

Check if the same lab product or an alternative is used in the 5 most similar protocols

Chemotherapeutic drugs, VP-16, DXR, PTX, CDDP, carboplatin, gemcitabine, 5-FU, cyclophosphamide, capecitabine, and vincristine were purchased from MedChemExpress. Topo IIα (catalog 12286), Smurf2 (catalog 12024), cPARP (catalog 5625), and Bim (catalog 2933) antibodies were purchased from Cell Signaling Technology Inc. Mcl-1 (sc-12756) and Topo IIβ (sc-55330) antibodies were purchased from Santa Cruz Biotechnology. Anti–phospho-histone H2AX (Ser139; γ-H2AX) antibody was purchased from MilliporeSigma (catalog 05–636). DAPI (catalog 62248) and secondary antibody Alexa Fluor 488 donkey anti-mouse (A32766) were purchased from Thermo Fisher Scientific. Other reagents and antibodies were the same as described previously (10 (link), 16 (link)).

Chen Z., Vallega K.A., Wang D., Quan Z., Fan S., Wang Q., Leal T., Ramalingam S.S, & Sun S.Y. (2024). DNA topoisomerase II inhibition potentiates osimertinib’s therapeutic efficacy in EGFR-mutant non–small cell lung cancer models. The Journal of Clinical Investigation, 134(10), e172716.

+ Open protocol

+ Expand

Cytotoxicity Assay for Sarcoma Cell Lines

Check if the same lab product or an alternative is used in the 5 most similar protocols

Between 1500 and 2000 cells per well of Plat-E, U2OS, SJSA1, HOS, and MG63 were seeded in a 384-well plate using a Multidrop Combi Reagent Dispenser (ThermoFisher Scientific) in 25 µL of media. Six thousand OHSU-SARC001 cells per well were seeded in a 96-well plate manually. Plat-E, U2OS, SJSA1, HOS, and MG63 were seeded using D10 media, whereas OHSU-SARC001 was seeded using DMEM:F12. Cells were cultured for 3–5 d depending on doubling time. Inhibitors (LY3023414, everolimus, bimiralisib, rapamycin, trametinib, doxorubicin [Selleckchem], vincristine [MedChemExpress)], actinomycin [MedChemExpress], DMSO, and staurosporine [Selleckchem]) were added using a D300 Digital Dispenser (Hewlett-Packard) ranging from 0.001 to 10 µM. Dose–response assays involving ipatasertib and afuresertib (MedChemExpress) with ranges of 0.001 to 10 µM were added manually to 96-well plates. Plat-E-, U2OS-, SJSA-, HOS-, and MG63-containing plates were incubated for 72 h at 37°C and 5% CO₂. OHSU-SARC001 cells were incubated for 6 d (given slow doubling time) at 37°C, 5% CO₂. Viability was measured using a Cell Counting Kit-8 (Bimake) and read on a Biotek Synergy 2 plate reader.

Choo F., Odinstov I., Nusser K., Nicholson K.S., Davis L., Corless C.L., Stork L., Somwar R., Ladanyi M., Davis J.L, & Davare M.A. (2022). Functional impact and targetability of PI3KCA, GNAS, and PTEN mutations in a spindle cell rhabdomyosarcoma with MYOD1 L122R mutation. Cold Spring Harbor Molecular Case Studies, 8(1), a006140.

+ Open protocol

+ Expand

Screening Spectrum Collection Compounds for OATP1B1 Inhibition

Check if the same lab product or an alternative is used in the 5 most similar protocols

Compounds from the Spectrum Collection, distributed in 80 wells of 96 well plates (100 nmol per well in 10 μl of DMSO), were screened for their inhibitory effectiveness against transport of E3S into CHO cells expressing OATP1B1; a total of 560 compounds were used. Each compound was diluted to a concentration of 20 μM, pH 7.4, to a final concentration of 2% dimethylsulfoxide (DMSO) using a VIAFLO multichannel electronic pipet (Integra Biosciences, Hudson, NH) ⁶⁵. The following compounds for prospective testing were purchased from MedChemExpress (Monmouth Junction, NJ): abamectin, asiaticoside, baloxavir, berbamine, bremelanotide, bromocriptine, cabazitaxel, doramectin, etoposide, lapatinib, mobocertinib, novobiocin, posaconazole, rifaximin, teniposide, umbralisib, vancomycin, vinblastine and vincristine. Pyronaridine tetraphosphate was purchased from BOC Sciences (Shirley, NY) and tilorone hydrochloride from Caymen Chemical Company (Ann Arbor, MI). These compounds were solubilized in DMSO at 20 mM prior to tested.

Lane T.R., Urbina F., Zhang X., Fye M., Gerlach J., Wright S.H, & Ekins S. (2022). Machine Learning Models Identify New Inhibitors for Human OATP1B1. Molecular pharmaceutics, 19(11), 4320-4332.

+ Open protocol

+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!